Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms

Neurourology and Urodynamics

Volumn 30, Issue 7, 2011, Pages 1214-1219

  Zinner, Norman R ^a   Dmochowski, Roger R ^b   Staskin, David R ^c   Siami, Paul F ^d   Sand, Peter K ^e   Oefelein, Michael G ^f  

^a Western Clinical ResearchInc   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Deaconess Clinic   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f ALLERGAN INC   (United States)

Author keywords

overactive bladder syndrome; trospium chloride; urgency urinary incontinence

Indexed keywords

PLACEBO; TROSPIUM CHLORIDE;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

AGED; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NORTROPANES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; URODYNAMICS;

EID: 80052047170     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21000     Document Type: Article

References (27)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49. (Pubitemid 36151708)
2. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306-14; discussion 1314-1305.
3. Stewart W, Van Rooyen T, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36. (Pubitemid 44175300)
4. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: A multicentre, community-based, randomized study. BJU Int 2007; 99: 836-44. (Pubitemid 46439555)
5. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: Report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19: 380-94.
6. Chapple CR,. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55: 33-46; discussion 50.
7. Kreder K, Mayne C, Jonas U,. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002; 41: 588-95. (Pubitemid 35333914)
8. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: Results of a 2-year, open-label extension study. BJU Int 2006; 98: 1025-32. (Pubitemid 44536453)
9. Dwyer P, Kelleher C, Young J, et al. Long-term benefits of darifenacin treatment for patient quality of life: Results from a 2-year extension study. Neurourol Urodyn 2008; 27: 540-7.
10. Kelleher CJ, Kreder KJ, Pleil AM, et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S616-30. (Pubitemid 36050143)
11. Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: A one-year study. Int Urol Nephrol 2002; 34: 43-9. (Pubitemid 36090223)
12. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95: 81-5. (Pubitemid 350020875)
13. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84. (Pubitemid 40248865)
14. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392-9. (Pubitemid 44175311)
15. Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: Results from a placebo-controlled interventional study. Urology 2008; 71: 449-54. (Pubitemid 351374733)
16. Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: Results from a multicenter phase III trial. J Urol 2007; 178: 978-83; discussion 983-974.
17. Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005; 174: 604-7. (Pubitemid 40981612)
18. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9. (Pubitemid 27517634)
19. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 2002; 11: 563-74. (Pubitemid 34876130)
20. Zinner N, Harnett M, Sabounjian L, et al. The overactive bladder-symptom composite score: A composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. J Urol 2005; 173: 1639-43. (Pubitemid 40524794)
21. D'Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008; 14: 291-301. (Pubitemid 351711980)
22. Brostrom S, Hallas J,. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009; 65: 309-14.
23. Cardozo L, Castro-Diaz D, Gittelman M, et al. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 512-9. (Pubitemid 44138259)
24. Staskin DR, Cardozo L,. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. Int J Clin Pract 2009; 63: 973-6.
25. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005; 44: 701-20. (Pubitemid 40994080)
26. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride is undetectable in the older human central nervous system (CNS). J Am Geriatr Soc 2010; 58: 1618-9.
27. Sandage B, Lerch G, Larsen G, et al. Trospium chloride does not cross the blood-brain barrier of male Long Evans rats. Neurology 2009; 72: A50.